18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the response to pyrotinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HER2-positive Breast Cancer

Age range

18 year–80 year

Sex eligibility

Female

Study type

Observational

Primary location

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pathologically confirmed HER2 positive breast cancer
Treated with Pyrotinib in the metastatic settings
Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine were included in this study

Exclusion criteria

Incomplete medical history
Loss of follow up

Treatment and study plan

Pyrotinib

Drug

Pyrotinib 400mg po qd

Primary outcomes

PFS

Time frame: Through study completion, an expected average of 12 months

Sponsors and collaborators

Lead sponsor

Biyun Wang, MD

Other

Registry information

Official study title

Pretreatment 18F-FDG Uptake Heterogeneity Predicts Response to Pyrotinib in Patients With Metastatic HER2-positive Breast Cancer

Important dates

Study start: 2018
Primary completion: 2020
Study completion: 2020
First posted: Feb 16, 2021
Registry last updated: Feb 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed